VIMTA LABS
|
|
BOM : 524394     NSE : VIMTALABS     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Apr 04,2025 |
Price(EOD): ₹ 925.40
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 2,054.39 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
VIMTA LABS | -7.5% | 5.3% | 136.8% |
SUN PHARMACEUTICAL INDUSTRIES | -1.5% | 9.1% | 9.1% |
DIVIS LABORATORIES | -4.9% | -0.6% | 59.1% |
CIPLA | -1.8% | 1% | 0.5% |
TORRENT PHARMACEUTICALS | 1.6% | 12.1% | 21.8% |
DR REDDYS LABORATORIES | -3% | -0.9% | -7.7% |
MANKIND PHARMA | 1.1% | 7.6% | 1.3% |
ZYDUS LIFESCIENCES | -2.2% | -0.6% | -9.3% |
LUPIN | -2.7% | 1% | 30.1% |
FUNDAMENTAL ANALYSIS OF VIMTA LABS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF VIMTA LABS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
34.78
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 59.16 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] 6.57
P/B Calculated based on Book Value of Rs 312.99 Cr
[Latest Year - Mar2024 - Consolidated Results ] 6.12
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 336.11 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
147% 196% 229% |
SHARE PRICE MOMENTUM OF VIMTA LABS
VIMTA LABS vs SENSEX
DEBT OF VIMTA LABS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.06 0.05 0.08 0.06 |
0.06 0.05 0.08 0.06 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF VIMTA LABS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2024 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF VIMTA LABS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
6.11% 10.64% 9.25% 2.94% |
20.57% 38.42% 52.91% 42.98% |
QtrlyTrend |
8 | |
Latest Qtr: Dec2024 | ||
Quarterly Result Analysis → |
VIMTA LABS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE MIDSMALLCAP | 1.4% | 9.3% | 8.2% |
BSE ALLCAP | -0.8% | 4.8% | 5.8% |
BSE SMALLCAP | -2% | 7.2% | 3.2% |
BSE HEALTHCARE | -2.3% | 5.7% | 14.3% |
You may also like the below Video Courses
FAQ about VIMTA LABS
Is VIMTA LABS good for long term investment?
As on Apr 04,2025, the Fundamentals of VIMTA LABS look Strong and hence it may be good for long term investment! See Financial Performance of VIMTA LABS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is VIMTA LABS UnderValued or OverValued?
As on Apr 04,2025, VIMTA LABS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of VIMTA LABS ?
As on Apr 04,2025, the Intrinsic Value of VIMTA LABS is Rs. 313.16 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 374.12
Fair Value [Median EV / Sales Model] : Rs. 313.16
Fair Value [Median Price / Sales Model] : Rs. 281.57
Estimated Median Fair Value of VIMTA LABS : Rs. 313.16
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.